Amgen Inc. (ETR:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 130.82B |
| Revenue (ttm) | 29.73B |
| Net Income (ttm) | 5.64B |
| Shares Out | n/a |
| EPS (ttm) | 10.41 |
| PE Ratio | 23.21 |
| Forward PE | 13.94 |
| Dividend | 8.59 (3.57%) |
| Ex-Dividend Date | Aug 22, 2025 |
| Volume | 4,642 |
| Average Volume | 1,081 |
| Open | 233.95 |
| Previous Close | 233.85 |
| Day's Range | 232.85 - 240.85 |
| 52-Week Range | 230.00 - 308.50 |
| Beta | 0.48 |
| RSI | 47.71 |
| Earnings Date | Oct 30, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Gordon Reid's Top Picks: Amgen, Qualcomm & United Rentals
Gordon Reid, President & CEO at Goodreid Investment Counsel, shares his top stock picks to watch in the market.
‘I fell in love with Dublin’s international atmosphere ... so I decided to stay and build my career in Ireland’
Leire Asua (Accenture) and Hamed Benyounis (Amgen)
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
Noteworthy ETF Inflows: SCHD, AMGN, TXN, LMT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Dividend Equity ETF (Symbol: SCHD) where we have detected an...
Amgen: Buy The Dip Opportunity
Vanguard Group Inc's Strategic Acquisition of Amgen Inc Shares
Vanguard Group Inc's Strategic Acquisition of Amgen Inc Shares
Validea Detailed Fundamental Analysis - AMGN
Below is Validea's guru fundamental report for AMGEN INC (AMGN). Of the 22 guru strategies we follow, AMGN rates highest using our Shareholder Yield Investor model based on the published strategy of M...
Amgen (AMGN) Sees Significant Spike in Investor Interest
Amgen (AMGN) Sees Significant Spike in Investor Interest
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for a new gastr...
AMGN Sees a Surge in Interest for Its Cancer Therapies
AMGN Sees a Surge in Interest for Its Cancer Therapies
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
US FDA to step up enforcement of pharma ads, sends enforcement letters
The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply wi...
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis
Amgen Inc. (NASDAQ: AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) o...
Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab
Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab
Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug
Amgen (AMGN) Gains Insights from ASCEND Study on Rocatinlimab for Dermatitis
Amgen (AMGN) Gains Insights from ASCEND Study on Rocatinlimab for Dermatitis
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab ...
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab for Atopic Dermatitis | AMGN stock news
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluati...
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 ASCEND ...
Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 ASCEND Study | AMGN stock news
If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today
You could have done worse -- or much better.
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
THOUSAND OAKS, Calif. and TOKYO , Sept.
September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de...
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m.
Today's Analyst Rating Update on Amgen (AMGN) | AMGN Stock News
Today's Analyst Rating Update on Amgen (AMGN) | AMGN Stock News